Takeda Pharma A/S
A/SActiveCVR 16406899Delta Park 45, 2665 Vallensbæk StrandWholesale of pharmaceutical and medical goods· NACE 4646Est. 1984 · 42 years old79 employees
Loading company…
Overview
Takeda Pharma A/S is a Danish A/S based in Vallensbæk Strand, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 1984, the company has 79 employees and reported revenue of DKK 1.1bn in its latest annual filing.
Revenue 2026
1.1B DKK
+1% vs 2025
EBITDA margin
10.6 %
+418% vs 2025
Net profit 2026
0.1B DKK
+629% vs 2025
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
73.2 %
StrongAmong the 30% highest rated companies in the industry
20222026
Liquidity ratioCurrent assets ÷ Short-term debt
3.8×
Very strongAmong the 20% highest rated companies in the industry
20222026
Return on assets (ROA)Net profit ÷ Total assets × 100
14.2 %
StrongAmong the 30% highest rated companies in the industry
20222026
EBITDA — year on year
DKK millionsKey figures
Annual report 2026| Revenue | 1.1B DKK | +1% |
| EBITDA | 0.1B DKK | +418% |
| Net profit | 0.1B DKK | +629% |
| Total assets | 0.6B DKK | +7% |
| Equity | 0.5B DKK | +24% |
| Employees | 79 | — |
Company information
Legal name
TAKEDA PHARMA A/S
CVR number
16406899
Legal form
Aktieselskab
NACE code
Founded
2 January 1984 · 42 years
Share capital
DKK 10,100,000
Employees
79 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2026-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør, af tre medlemmer af bestyrelsen i forening, af bestyrelsens formand og et andet medlem af bestyrelsen i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hermed beslægtede varer.
(no translation available)
Contact
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2026), Takeda Pharma A/S reported revenue of DKK 1.1bn, an increase of 1% on the year before. The figures on this page draw on 5 annual filings covering 2022 to 2026. The bottom line showed a net profit of DKK 88.6m, and the EBITDA margin stood at 10.6%.
At the end of 2026, equity financed 73.2% of the balance sheet, and current assets covered short-term debt 3.8 times.
Financials
Revenue
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 1,112,753 | 1,102,419 | 1,118,710 | 1,061,206 | 910,058 |
| Staff expenses | -97,320 | -96,205 | -91,609 | -93,146 | -104,459 |
| EBITDA | 118,342 | 22,830 | 346,095 | 27,436 | 49,530 |
| Depreciation & amort. | -5,330 | -5,582 | -8,506 | -6,594 | -8,264 |
| EBIT | 113,012 | 17,248 | 337,589 | 20,842 | 41,266 |
| Net financials | 1,155 | -103 | -1,862 | 10 | 1,455 |
| Profit before tax | 114,167 | 17,145 | 335,727 | 20,852 | 42,721 |
| Tax | 25,526 | 4,983 | 74,505 | 7,279 | 10,926 |
| Net profit | 88,641 | 12,162 | 261,222 | 13,573 | 31,795 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | 623,480 | 581,334 | 582,370 | 485,750 | 622,293 |
| Equity | 456,501 | 368,294 | 355,951 | 94,892 | 81,238 |
| Long-term debt | 5,243 | 9,360 | 10,701 | 12,659 | 14,219 |
| Short-term debt | 161,736 | 203,680 | 215,718 | 375,272 | 525,597 |
| Total debt | 166,979 | 213,040 | 226,419 | 387,931 | 539,816 |
Financial ratios
5-year trendEBITDA margin
10.6 %
20222026
Equity ratio
73.2 %
StrongAmong the 30% highest rated companies in the industry
20222026
Return on equity
19.4 %
StrongAmong the 40% highest rated companies in the industry
20222026
Net profit margin
8.0 %
Very strongAmong the 20% highest rated companies in the industry
20222026
Asset turnover
1.78×
AverageAround the average of companies in the same industry
20222026
Debt / equity
0.37×
StrongAmong the 30% highest rated companies in the industry
20222026
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginAverage
Around the average of companies in the same industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery strong
Among the 20% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 20% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Strong
Among the 30% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 40% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 30% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 20% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 20% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioStrong
Among the 30% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 40% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalStrong
Among the 40% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 40% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioStrong
Among the 30% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 20% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 30% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityStrong
Among the 30% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery strong
Among the 20% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery strong
Among the 20% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 10% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 30% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 40% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 20% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 30% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtStrong
Among the 30% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2026Filed via CVR / Virk · Period 2025-04-01 – 2026-03-31
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EC Management | Management | 2026 |
Former (25)
RK Chief Executive Officer | Chief Executive Officer | 2021 – 2025 |
DB Deputy | Deputy | 1984 – 1991 |
SM Deputy | Deputy | 2013 – 2014 |
HK Deputy | Deputy | 1995 – 1999 |
JM Chief Executive Officer | Chief Executive Officer | 1995 – 1997 |
AL Deputy | Deputy | 1984 – 1989 |
HK Deputy | Deputy | 2002 – 2003 |
GA Chief Executive Officer | Chief Executive Officer | 2007 – 2017 |
RK Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
AB Management | Management | 1984 – 1995 |
KS Management | Management | 2026 – 2026 |
SW Deputy | Deputy | 1984 – 1995 |
CM Deputy | Deputy | 2007 – 2013 |
LB | Deputy | 2013 – 2015 |
GJ Deputy | Deputy | 1984 – 1995 |
BG Deputy | Deputy | 1984 – 1998 |
BM Deputy | Deputy | 2014 – 2015 |
LP Chief Executive Officer | Chief Executive Officer | 2017 – 2021 |
| Audit | 1999 – 2003 | |
BS Management | Management | 1998 – 2007 |
JL Deputy | Deputy | 2015 – 2019 |
MJ Deputy | Deputy | 2015 – 2017 |
GF Management | Management | 2025 – 2026 |
CR Chief Executive Officer | Chief Executive Officer | 2025 – 2025 |
JM Chief Executive Officer | Chief Executive Officer | 1997 – 1998 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
KS Chairman | Chairman | 2026 |
EC Board of Directors | Board of Directors | 2026 |
JL Board of Directors | Board of Directors | 2019 |
MK Board of Directors | Board of Directors | 2026 |
Former (62)
JC Board of Directors | Board of Directors | 2003 – 2007 |
HJ Board of Directors | Board of Directors | 2002 – 2003 |
LR Board of Directors | Board of Directors | 2014 – 2016 |
PH Chairman | Chairman | 1999 – 2000 |
LF Board of Directors | Board of Directors | 1999 – 2000 |
CP Board of Directors | Board of Directors | 2002 – 2003 |
GW Chairman | Chairman | 2013 – 2014 |
OL Board of Directors | Board of Directors | 1984 – 1999 |
KB Board of Directors | Board of Directors | 2013 – 2015 |
RB Deputy Chairman | Deputy Chairman | 1999 – 2002 |
TG Board of Directors | Board of Directors | 2003 – 2005 |
BJ Board of Directors | Board of Directors | 1984 – 1992 |
HS Board of Directors | Board of Directors | 2012 – 2014 |
HK Board of Directors | Board of Directors | 1984 – 1995 |
BE Board of Directors | Board of Directors | 1984 – 1991 |
CD Board of Directors | Board of Directors | 2002 – 2007 |
ER Board of Directors | Board of Directors | 2002 – 2003 |
GA Board of Directors | Board of Directors | 2014 – 2017 |
DL Chairman | Chairman | 2014 – 2016 |
SH Board of Directors | Board of Directors | 2002 – 2003 |
BW Board of Directors | Board of Directors | 1999 – 2000 |
JL Chairman | Chairman | 2016 – 2017 |
OT Board of Directors | Board of Directors | 1984 – 1991 |
HT Board of Directors | Board of Directors | 1984 – 1996 |
CM Board of Directors | Board of Directors | 2003 – 2003 |
MH Board of Directors | Board of Directors | 2007 – 2019 |
BG Board of Directors | Board of Directors | 1998 – 1999 |
BM Board of Directors | Board of Directors | 2015 – 2021 |
TV Chairman | Chairman | 1984 – 1999 |
JD Board of Directors | Board of Directors | 2007 – 2011 |
GH Board of Directors | Board of Directors | 2021 – 2026 |
HL Deputy Chairman | Deputy Chairman | 1984 – 1999 |
GI Board of Directors | Board of Directors | 1984 – 1995 |
BK Board of Directors | Board of Directors | 1984 – 1991 |
DJ Chairman | Chairman | 2021 – 2023 |
GD Board of Directors | Board of Directors | 1984 – 1999 |
BS Board of Directors | Board of Directors | 2007 – 2009 |
VM Chairman | Chairman | 2023 – 2024 |
TD Chairman | Chairman | 2002 – 2003 |
ØA Board of Directors | Board of Directors | 1984 – 1996 |
IR Chairman | Chairman | 2017 – 2021 |
RB Chairman | Chairman | 2003 – 2012 |
BI Chairman | Chairman | 1984 – 1996 |
MJ Board of Directors | Board of Directors | 2011 – 2013 |
CA Board of Directors | Board of Directors | 2003 – 2012 |
SN Chairman | Chairman | 2012 – 2013 |
DP Board of Directors | Board of Directors | 2012 – 2014 |
PJ Board of Directors | Board of Directors | 1984 – 1991 |
NH Board of Directors | Board of Directors | 2016 – 2021 |
AM Board of Directors | Board of Directors | 1995 – 1990 |
BK Board of Directors | Board of Directors | 1984 – 1991 |
PR Board of Directors | Board of Directors | 1984 – 1989 |
CR Chairman | Chairman | 2026 – 2026 |
RS Board of Directors | Board of Directors | 2002 – 2003 |
BT Board of Directors | Board of Directors | 1999 – 2002 |
UE Board of Directors | Board of Directors | 2003 – 2003 |
AE Board of Directors | Board of Directors | 2017 – 2021 |
TT Board of Directors | Board of Directors | 1984 – 1993 |
JM Board of Directors | Board of Directors | 1984 – 1991 |
PH Chairman | Chairman | 2003 – 2003 |
RE Board of Directors | Board of Directors | 2009 – 2012 |
ON Board of Directors | Board of Directors | 1995 – 1998 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Takeda Pharmaceuticals International AG | Company | 100% | 100% | 2019 |
| Company | 100% | 100% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Takeda Pharmaceuticals International AG
Takeda Pharma A/S Board network connections
Board members of Takeda Pharma A/S also hold positions in 28 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jesper Mailind | Chief Executive Officer | 7 companiesMany roles |
| Alejandra Maria Cristina Bonifacini Mørk | Board of Directors | 6 companiesMany roles |
| Jesper Christian Schrøder | Board of Directors | 4 companies |
| Jørgen Moestrup | Chief Executive Officer | 3 companies |
| Helle Skov Wagner | Board of Directors | 2 companies |
| Helle Kit Knudsen | Deputy | 1 company |
| Lars Patrik Mikael Forsell | Chief Executive Officer | 1 company |
| Bent Eichstedt Nielsen | Board of Directors | 1 company |
| Conny Ditlevsen | Board of Directors | 1 company |
| Helge Tovborg-Jensen | Board of Directors | 1 company |
| Bo Thomas Dybbro | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of Takeda Pharma A/S?
Takeda Pharma A/S is registered with CVR / Virk under CVR 16406899.
What is the revenue of Takeda Pharma A/S?
Takeda Pharma A/S reported revenue of DKK 1.1bn in 2026.
How many employees does Takeda Pharma A/S have?
Takeda Pharma A/S employs 79 people as of the latest annual report.
Who is the chairman of Takeda Pharma A/S?
Koki Sato chairs the board of Takeda Pharma A/S, in role since 2026.
Where is Takeda Pharma A/S headquartered?
Takeda Pharma A/S's registered address is Delta Park 45.